Top 10 Companies in the (S)-N-Boc-3-Bromophenylalanine (CAS 82278-73-7) Market (2026): Market Leaders Powering Global Innovation

MARKET INSIGHTS

Global (S)-N-Boc-3-Bromophenylalanine (CAS 82278-73-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

(S)-N-Boc-3-Bromophenylalanine (CAS 82278-73-7) is a Boc-protected unnatural amino acid derivative featuring a bromine substituent at the meta position of the phenylalanine aromatic ring. It serves as a critical building block in peptide synthesis, medicinal chemistry, and the development of pharmaceutical intermediates. The compound’s well-defined stereochemistry and reactive bromine handle make it particularly valuable in cross‑coupling reactions, enabling chemists to construct structurally complex molecules with high precision.

The market is witnessing steady growth driven by rising demand for novel peptide‑based therapeutics, increased activity in drug discovery programs, and the broader expansion of contract research and manufacturing organizations worldwide. Furthermore, the growing adoption of Boc‑protected amino acid derivatives in solid‑phase peptide synthesis workflows continues to reinforce demand across academic, biotechnology, and pharmaceutical end‑user segments. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Combi‑Blocks, among others.

(S)-N-Boc-3-Bromophenylalanine (CAS 82278-73-7) Market – View in Detailed Research Report

---

🔟 1. Bachem AG

Headquarters: Binningen, Switzerland
Key Offering: High‑purity Boc‑protected amino acids and peptide synthesis intermediates

Bachem AG is a global leader in peptide chemistry, providing a robust portfolio of chiral amino acids for pharmaceutical and biotechnology applications. Their advanced synthetic platforms enable rapid scale‑up and consistent enantiomeric excess, making them a preferred supplier for large‑scale peptide drug development.

Innovation & Sustainability Initiatives:

• Investment in green chemistry processes to reduce solvent usage
• Continuous improvement of asymmetric synthesis routes to lower catalyst loading
• Commitment to ISO 9001 and GMP compliance across all manufacturing sites

---

9️⃣ 2. Merck KGaA (Sigma‑Aldrich)

Headquarters: Darmstadt, Germany
Key Offering: Comprehensive portfolio of chiral building blocks and fine chemicals

Merck KGaA, through its Sigma‑Aldrich division, supplies a wide range of high‑purity amino acids, including (S)-N‑Boc‑3‑Bromophenylalanine. Their extensive global distribution network and strong quality assurance framework support both research and commercial pharmaceutical manufacturing.

Innovation & Sustainability Initiatives:

• Adoption of renewable feedstocks for synthetic routes
• Implementation of digital traceability systems for batch tracking
• Targeted reduction of carbon footprint in production facilities

---

8️⃣ 3. Tokyo Chemical Industry Co., Ltd. (TCI)

Headquarters: Tokyo, Japan
Key Offering: Specialty amino acids and custom synthesis services

TCI is a leading provider of fine chemicals, offering a broad range of Boc‑protected amino acids. Their state‑of‑the‑art synthesis laboratories support custom orders, enabling rapid turnaround for research and development projects.

Innovation & Sustainability Initiatives:

• Development of catalyst‑free synthetic routes to reduce waste
• Collaboration with universities to advance asymmetric synthesis techniques
• Focus on achieving zero‑hazard operations in line with ISO 14001

---

7️⃣ 4. Iris Biotech GmbH

Headquarters: Munich, Germany
Key Offering: Custom synthesis of unnatural amino acids and peptide intermediates

Iris Biotech specializes in delivering high‑quality chiral building blocks tailored to client specifications. Their agile production model supports rapid prototyping and small‑batch manufacturing for academic and industrial research.

Innovation & Sustainability Initiatives:

• Implementation of high‑throughput synthesis platforms
• Use of recyclable solvents in synthetic processes
• Partnerships with environmental NGOs to monitor chemical safety

---

6️⃣ 5. Chem‑Impex International, Inc.

Headquarters: Santa Ana, USA
Key Offering: Fine chemical manufacturing and custom synthesis services

Chem‑Impex International offers a portfolio of specialty amino acids and custom synthesis solutions, catering to both pharmaceutical and academic markets. Their flexible batch sizes and rapid lead times make them a valuable partner for early‑stage drug discovery.

Innovation & Sustainability Initiatives:

• Adoption of continuous flow chemistry for scale‑up
• Implementation of waste‑minimization protocols
• Commitment to achieving GHG reduction targets by 2030

---

5️⃣ 6. Biosynth AG

Headquarters: Glarus, Switzerland
Key Offering: Chiral amino acids and specialty intermediates

Biosynth AG provides high‑purity Boc‑protected amino acids with stringent quality controls. Their focus on process development ensures consistent enantiomeric excess and scalability for commercial production.

Innovation & Sustainability Initiatives:

• Development of energy‑efficient synthesis routes
• Use of bio‑based reagents to reduce environmental impact
• Participation in industry consortia for sustainable chemical manufacturing

---

4️⃣ 7. AnaSpec, Inc.

Headquarters: North Carolina, USA
Key Offering: Research‑grade specialty chemicals and custom synthesis

AnaSpec delivers a wide range of research‑grade chemicals, including (S)-N‑Boc‑3‑Bromophenylalanine, with rapid turnaround and flexible batch sizes. Their focus on academic and biotech clients supports early‑stage development.

Innovation & Sustainability Initiatives:

• Implementation of green chemistry training programs for staff
• Use of recyclable packaging materials
• Support for open‑access research collaborations

---

3️⃣ 8. AAPPTec, LLC

Headquarters: Irvine, USA
Key Offering: Custom synthesis of chiral amino acids and intermediates

AAPPTec specializes in providing high‑purity, enantiomerically pure building blocks for pharmaceutical R&D. Their rapid scale‑up capabilities and stringent QC ensure compliance with regulatory standards.

Innovation & Sustainability Initiatives:

• Adoption of solvent‑free synthesis techniques
• Use of renewable energy in manufacturing facilities
• Continuous improvement of process safety protocols

---

2️⃣ 9. GL Biochem (Shanghai) Ltd.

Headquarters: Shanghai, China
Key Offering: Large‑scale production of chiral amino acids and specialty intermediates

GL Biochem has rapidly expanded its production capacity to meet growing demand for high‑purity Boc‑protected amino acids. Their investment in advanced synthesis platforms supports large‑volume orders for both domestic and international markets.

Innovation & Sustainability Initiatives:

• Implementation of automated synthesis lines to reduce labor intensity
• Focus on waste‑reduction and recycling programs
• Compliance with China’s new chemical safety regulations

---

1️⃣ 10. Sinopep Allsino Biopharmaceutical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity chiral amino acids and custom synthesis solutions

Sinopep Allsino provides a comprehensive range of specialty amino acids, including (S)-N‑Boc‑3‑Bromophenylalanine, with a focus on meeting stringent regulatory requirements for pharmaceutical development.

Innovation & Sustainability Initiatives:

• Adoption of green chemistry principles in all synthesis routes
• Investment in renewable energy for production facilities
• Collaboration with academic institutions for sustainable chemical research

---

Download FREE Sample Report: (S)-N-Boc-3-Bromophenylalanine (CAS 82278-73-7) Market – View in Detailed Research Report

Get Full Report: (S)-N-Boc-3-Bromophenylalanine (CAS 82278-73-7) Market – View in Detailed Research Report

---

📈 Outlook: The Future of (S)-N-Boc-3-Bromophenylalanine Market

The compound’s unique combination of Boc protection and a reactive bromine handle positions it as a key building block for next‑generation peptide therapeutics, antibody‑drug conjugates, and advanced chemical biology tools. Market dynamics indicate continued expansion driven by the rapid growth of peptide‑based drug pipelines, increased adoption of solid‑phase peptide synthesis, and the rising demand for chiral purity in active pharmaceutical ingredients.

Key growth levers include:

• Expansion of peptide drug pipelines across oncology, metabolic, and infectious disease indications.
• Increased outsourcing of fine‑chemical synthesis by pharmaceutical and biotechnology companies.
• Emerging applications in proteomics and activity‑based protein profiling.
• Strategic partnerships between specialty suppliers and contract manufacturing organizations.

🔮 Future Trends

Emerging trends that are likely to shape the market include:

• Development of next‑generation ADC platforms requiring versatile linker chemistry.
• Integration of AI‑driven synthetic route design to accelerate chiral resolution.
• Adoption of continuous flow and green chemistry technologies to reduce cost and environmental impact.
• Growth of regional manufacturing hubs in Asia‑Pacific and North America to meet demand for rapid, high‑purity supply.
• Regulatory tightening on chiral purity and environmental safety for organobromine compounds.

Overall, the (S)-N‑Boc‑3‑Bromophenylalanine market is poised for robust growth, driven by innovation in peptide therapeutics, advanced synthesis technologies, and a global shift toward high‑purity, sustainable chemical manufacturing.